Corona Genome Sequencing: Start-up "nanozoo" Launches Portal for Free Data Analysis
Advertisement
The central German start-up company "nanozoo" – a member of the InfectoGnostics research campus in Jena – has launched a portal for the free analysis and processing of raw data from the genome sequencing of SARS-CoV-2 isolates. Within a few hours, the data of registered users will be processed and made available. The resulting genome sequences are checked against the quality metrics defined by the Robert Koch Institute, which provide information on whether a data set meets the quality standards for submission to the federal institute.
The three founders of "nanozoo": Martin Hölzer, Christian Brandt, Adrian Viehweger (from left).
nanozoo
The the portal nanozoo.cloud, which supports laboratories in processing raw data from "MinION" genome sequencing. With a subsequent update, "Illumina" data can also be analysed. For raw data from sequencing of SARS-CoV-2 samples, the service is provided free of charge for registered users from Germany. "For us, this is an opportunity to stress test our newly developed portal and at the same time contribute to the fight against the Corona pandemic. For the laboratories, on the other hand, an otherwise very time-consuming, manual step to a usable result is eliminated," explains Dr. Christian Brandt, molecular biologist at the Institute for Infectious Medicine and Hospital Hygiene at the Jena University Hospital and one of the three company founders.
The complete analysis and processing of the raw data takes – depending on the size of the data set – only between 30 minutes and a few hours. The data continues to belong completely to the submitting users and can then be transmitted independently to the RKI. Due to the danger of unrecognised corona mutations, on 18 January the German government called for the submission of genome sequence data from patient samples that had tested positive for SARS-CoV-2 and offered a payment of 220 euros per sequencing if the genome quality was good enough. For this purpose, nanozoo has also integrated a quality metric into the portal that provides information on whether the data meet the RKI quality standards and are suitable for transmission.
In addition, the three entrepreneurs, together with other partners from Berlin, Jena and Bad Langensalza, were involved in a current, pre-published study in which the SARS-CoV-2 genome from Thuringian samples was compared with virus lines spread in Germany, Europe and worldwide.
Other news from the department research and development
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
New Opportunity for Cancer Therapy: Miniature Lab Provides Insights into Metastases Development - Fraunhofer IWS Develops Microphysiological Systems for Cultivation of Tumor Tissue Sections in Joint Effort
Kill the cancer, not the patient: New toxicity testing approach could make chemo drugs safer - National Cancer Institute grants $1M to test 3 chemo drugs
Pioneering discovery of an odor-detecting receptor enhancer
Modified crops reveal hidden cost of resistance
MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program - First HuCAL-based Antibody to Enter Clinical Trial in Second Indication
Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize
New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future
